Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,552,688
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.67
  • Price/Sales 6.78
  • Price/Cash Flow 18.34
  • Price/Book 15.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.52 +0.64%
on 04/25/18
50.63 -7.53%
on 04/10/18
-2.74 (-5.53%)
since 03/26/18
3-Month
46.52 +0.64%
on 04/25/18
57.72 -18.88%
on 01/29/18
-11.32 (-19.47%)
since 01/26/18
52-Week
38.05 +23.05%
on 04/27/17
58.37 -19.79%
on 01/23/18
+9.46 (+25.32%)
since 04/26/17

Most Recent Stories

More News
Emisphere Amends License Agreement with Novo Nordisk

Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the development and commercialization...

EMIS : 0.6150 (-1.60%)
NVO : 46.82 (-0.13%)
Global Biopharmaceutical Market 2018-2023 - Key Players are Roche, Amgen, Novo Nordisk, AbbVie and Sanofi

The "Global Biopharmaceutical Market Report & Forecast (2018-2023)" report has been added to ResearchAndMarkets.com's offering.

NVO : 46.82 (-0.13%)
AMGN : 175.60 (+0.44%)
Xultophy® approved in Canada for the treatment of adults with type 2 diabetes

Xultophy® approved in Canada for the treatment of adults with type 2 diabetes

NVO : 46.82 (-0.13%)
Tessa Therapeutics announces new Board Member and increase of recent funding round

-- Göran Ando, former Chairman of Novo Nordisk A/S, to join Tessa's Board of Directors

NVO : 46.82 (-0.13%)
Novo Nordisk Obtains Licence for Sickle Cell Disease Program

Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

LGND : 154.72 (-4.36%)
NVO : 46.82 (-0.13%)
ENTA : 87.91 (+0.47%)
REGN : 316.17 (+1.34%)
Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Novo Nordisk A/S (NYSE:NVO),...

GG : 13.75 (-1.43%)
CLNS : 6.02 (+1.35%)
NVO : 46.82 (-0.13%)
DNB : 116.70 (+0.22%)
IMAX : 23.30 (-1.27%)
BAM : 38.23 (-0.62%)
FDA approves inclusion of data from safety outcomes trial in the Tresiba® label

Novo Nordisk today announced that the US Food and Drug Administration (FDA) approved updates to the prescribing information (PI) for Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL to include...

NVO : 46.82 (-0.13%)
FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba(R) label

Bagsvaerd, Denmark, 26 March 2018 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an update to the US prescribing information for Tresiba(R) (insulin degludec)...

NVO : 46.82 (-0.13%)
Ozempic(R) approved in Japan for the treatment of type 2 diabetes

Bagsvaerd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic(R) (semaglutide), a new once-weekly analogue of human glucagon-like...

NVO : 46.82 (-0.13%)
Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsvaerd, Denmark, 22 March 2018 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted:

NVO : 46.82 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 47.31
1st Resistance Point 47.09
Last Price 46.82
1st Support Level 46.59
2nd Support Level 46.31

See More

52-Week High 58.37
Fibonacci 61.8% 50.61
Fibonacci 50% 48.21
Last Price 46.82
Fibonacci 38.2% 45.81
52-Week Low 38.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar